# Suleman Adil

Suleman Adil is a healthtech commercial leader focused on sales, go-to-market strategy and NHS adoption. Their posts examine how procurement, customer use and clinical workflow affect whether healthcare technology delivers lasting value.

- Profile: https://b2binfluencer.marketing/creators/suleman-adil/
- LinkedIn: https://www.linkedin.com/in/suleman-adil
- Topics: leadership, sales, healthcare, sales-leadership
- Based on 15 dated posts, latest 2026-08-31

## Summary

Suleman Adil is most useful for testing NHS healthtech adoption, procurement and value after pilot.

- Best for: Healthtech suppliers selling ambient voice or clinical documentation to NHS trusts needing adoption strategy.
- Not for: Consumer wellness app campaigns for UK consumers aged 18 to 34.
- Check first: Confirm source data, fees, scope, availability, and audience insights before contacting.

### Takeaways

- Online consultation submissions rose from 5.7 million to 9.8 million; supplier practice count stayed flat.
- Submissions do not measure completed consultations or unique patients, Adil cautions.
- Ambient voice implementation counts do not show continued clinician use, patient flow or contract renewal.

## Main ideas

- **A framework place or a pilot does not prove NHS technology is being used**: Suleman Adil returns to the same distinction across several posts: a procurement footprint shows that a supplier has secured access, not that the technology has changed clinical work. On the NHS Shared Business Services AI framework, worth £900m and running to 2035, they argue the real opportunity is not another route to market but how the NHS buys, adopts and governs technology. They sum up the risk as procurement at scale not automatically meaning adoption at scale: trusts still need digital maturity, clinical safety governance, implementation support and workforce readiness. On ambient voice technology, they read an implementation chart as evidence of a fragmented market, not a settled one. Buyers should ask suppliers how widely the tool is used within each organisation, whether clinicians keep using it after a pilot, whether documentation time or patient flow improves, whether it integrates with the EPR, and whether contracts scale or are renewed.
- **HealthTech is not just another software vertical, and a large footprint can hide lost trust**: Their commercial argument is that a place on a major framework or thousands of customers does not make a defensible market position. Warning signs sit below the surface: stretched customer success, slow support, painful onboarding, unresolved product issues, integrations that do not work as expected, and roadmaps shaped internally rather than by customers. Reported numbers can still look healthy—ARR growing, cross-sell increasing, pipeline strong—which is precisely when danger starts. As they put it, you can grow ARR while simultaneously weakening the ARR you already have. Healthcare buyers weigh workflow, trust, implementation, clinical impact and whether a supplier understands their environment. An apparent moat may turn out to be customer inertia, while framework change, evolving procurement routes and AI erode older advantages.
- **The measures they emphasize: utilisation, clinician retention, time saved, outcomes and renewal rates**: Rather than only criticising the available numbers, Suleman Adil names the measures that would show who is winning. In the ambient voice post, they call for utilisation, clinician retention, time saved, outcomes achieved and renewal rates alongside the implementation chart. They argue the next phase of the market will be won by suppliers that turn early deployments into measurable, repeatable outcomes proving the technology is safe, adopted and embedded in clinical practice. They also note that online consultation submissions measure activity, not completed consultations or unique patients; practice size, opening hours and how patients are directed into each channel affect supplier-level counts. These caveats still leave low submission counts raising valid questions about how embedded the systems actually are.
- **Sales leadership: grit, forecast delivery and holding standards under pressure**: In shorter posts about their commercial work, Suleman Adil describes the last day of a quarter as a side of sales leadership people do not always see: resilience, belief and at least the appearance of calm when everything hinges on a handful of conversations. They frame the job as rallying the team through objections, delays and last-minute curveballs, and keeping belief alive as the clock runs down. Credit consistently goes to the team for accountability and refusing to let standards slip under pressure.

## Work to read

- [NHS online consultation use, measured supplier by supplier](https://www.linkedin.com/posts/suleman-adil_nhs-primarycare-healthtech-activity-7496195066617597952-YNFU)
- [Ambient voice tech in NHS trusts: what implementation counts do and do not show](https://www.linkedin.com/posts/suleman-adil_healthtech-nhs-ambientai-activity-7495799831395737600-sTwZ)
- [The £900m NHS Shared Business Services AI framework and what procurement can do](https://www.linkedin.com/posts/suleman-adil_digitalhealth-nhs-aiinhealthcare-activity-7470746891060744192-wfty)
- [HealthTech is not generic SaaS: footprint versus customer trust](https://www.linkedin.com/posts/suleman-adil_healthtech-healthcaretech-commercialleadership-activity-7492878840051077120-XOid)
- [Career move: leaving the Sales Director role for primary care at OneAdvanced](https://www.linkedin.com/posts/suleman-adil_leadership-salesleadership-commercialleadership-activity-7483083699564027904-mjra)
- [Closing out FY26: how a quarter actually lands](https://www.linkedin.com/posts/suleman-adil_as-we-close-out-fy26-im-reminded-that-no-activity-7433216878338289664-RDTB)

## Brand relationships

- **OneAdvanced Health & Care** (employment)

## Partnerships

Suleman Adil's posts do not offer sponsorship, branded-content or media-kit services, and there is no published rate card, audience pack or partner-terms page. The only commercial arrangement described is independent advisory work for healthtech leadership teams: a candid outside review of a company's commercial model, customer journey, retention risk and go-to-market strategy, offered in an August 2026 post, and a similar invitation in another August 2026 post to discuss framework strategy and end-to-end customer journeys. Both describe an informal conversation rather than a packaged service. The first conversation is free and explicitly not a pitch; neither post states a fee, scope, commitment length or deliverable. No official partnership or sponsorship inquiry route is published; the posts direct interested parties to send a LinkedIn message.

## Alternatives

- John C.: Choose John C. when the adoption case needs to be argued at board and CIO level rather than from market data. The posts cover what sitting on a board of directors teaches an executive: questioning whether strategy is clear, investments are sensibly prioritised, risk is managed, the company is financially viable and the right leaders are being cultivated. They also explain why current cybersecurity knowledge is now table stakes for a healthcare CIO, including medical device and IoMT risk, identity and access management, zero trust, ransomware resilience and clinical downtime. That is the right voice when a supplier wants to frame an ambient voice or clinical documentation decision as a governance, risk and patient-safety question, or reach a trust's executive team rather than its commercial function.
- Sana Dalvi: Choose Sana Dalvi when a campaign needs to speak credibly about what happens after a trust signs: implementation delivery and clinical change management. The posts describe in-person site visits across EHR implementations and problems that emerge on the floor: device-to-user ratios of 1:3 at peak times, with nurses queuing to chart; equipment marked available but unreliable or unused; workarounds that have quietly become permanent; and no backup power plan for downtime devices. The second post explains why clinicians ask how long a change will take, distinguishing a saturated team from a resistant one. It also shares methods that worked: one trusted person per shift who can answer questions in real time, showing up the same day rather than next week, handing out single-page reference guides on the floor, and acknowledging what else the unit is carrying before adding more. That is the practical detail a supplier needs for a campaign about clinician adoption and retention rather than procurement.
- Matthew Guldin: Choose Matthew Guldin when the deliverable is about presenting evidence and outcomes persuasively. The posts discuss HIMSS conference proposals and argue that a strong Health IT proposal starts with a specific baseline problem — what was not working, who was affected and what things looked like before — then shows credible before-and-after results, such as length of stay moving from 4.8 to 4.4 days, a workflow saving clinicians 20 minutes a day, denials down 15%, or $2 million in savings with the source explained. They also urge presenters to say what did not work, what was underestimated and what metric did not move, and to keep a provider/vendor case study from turning into a product pitch. The repeated line, "Implementation isn't an outcome. Impact is," suits a supplier building a trust-facing case study or a conference submission that can withstand scrutiny.

---
AI-assisted summary of public posts. Audience demographics are not available. Engagement appears only where we checked recent posts. Method: https://b2binfluencer.marketing/methodology/